Robert Torka
YOU?
Author Swipe
View article: Discovery of <i>N</i>-[4-(Quinolin-4-yloxy)phenyl]benzenesulfonamides as Novel AXL Kinase Inhibitors
Discovery of <i>N</i>-[4-(Quinolin-4-yloxy)phenyl]benzenesulfonamides as Novel AXL Kinase Inhibitors Open
The overexpression of AXL kinase has been described in many types of cancer. Due to its role in proliferation, survival, migration, and resistance, AXL represents a promising target in the treatment of the disease. In this study we present…
View article: <scp>GAS</scp>6‐expressing and self‐sustaining cancer cells in 3D spheroids activate the <scp>PDK</scp>‐<scp>RSK</scp>‐<scp>mTOR</scp> pathway for survival and drug resistance
<span>GAS</span>6‐expressing and self‐sustaining cancer cells in 3D spheroids activate the <span>PDK</span>‐<span>RSK</span>‐<span>mTOR</span> pathway for survival and drug resistance Open
AXL receptor tyrosine kinase ( RTK ) inhibition presents a promising therapeutic strategy for aggressive tumor subtypes, as AXL signaling is upregulated in many cancers resistant to first‐line treatments. Furthermore, the AXL ligand growth…
View article: Phospho-AXL is widely expressed in glioblastoma and associated with significant shorter overall survival
Phospho-AXL is widely expressed in glioblastoma and associated with significant shorter overall survival Open
Receptor tyrosine kinase AXL (RTK-AXL) is regarded as a suitable target in glioblastoma (GBM) therapy. Since AXL kinase inhibitors are about to get approval for clinical use, patients with a potential benefit from therapy targeting AXL nee…
View article: Inhibiting receptor tyrosine kinase AXL with small molecule inhibitor BMS-777607 reduces glioblastoma growth, migration, and invasion <i>in vitro</i> and <i>in vivo</i>
Inhibiting receptor tyrosine kinase AXL with small molecule inhibitor BMS-777607 reduces glioblastoma growth, migration, and invasion <i>in vitro</i> and <i>in vivo</i> Open
Collectively, these data strongly suggest that targeting RTK-AXL with BMS-777607 could represent a novel and potent regimen for the treatment of primary and recurrent GBM.